Anaptysbio (ANAB) EBIT Margin (2016 - 2025)
Anaptysbio's EBIT Margin history spans 10 years, with the latest figure at 21.68% for Q4 2025.
- For Q4 2025, EBIT Margin rose 6036.0% year-over-year to 21.68%; the TTM value through Dec 2025 reached 1.57%, up 19611.0%, while the annual FY2025 figure was 1.17%, 12476.0% up from the prior year.
- EBIT Margin reached 21.68% in Q4 2025 per ANAB's latest filing, down from 69.41% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 976.29% in Q4 2023 to a low of 3273.09% in Q1 2022.
- Average EBIT Margin over 5 years is 874.82%, with a median of 275.57% recorded in 2024.
- Peak YoY movement for EBIT Margin: tumbled -313738bps in 2021, then surged 264367bps in 2024.
- A 5-year view of EBIT Margin shows it stood at 3081.8% in 2021, then soared by 83bps to 519.46% in 2022, then skyrocketed by 288bps to 976.29% in 2023, then crashed by -104bps to 38.68% in 2024, then soared by 156bps to 21.68% in 2025.
- Per Business Quant, the three most recent readings for ANAB's EBIT Margin are 21.68% (Q4 2025), 69.41% (Q3 2025), and 117.55% (Q2 2025).